About Us
Overview
Business Model
Milestones
Our Presence
Board of Directors
Mission, Vision & Values
Environment
Granules India Limited - 25th Anniversary Logo

Vertical Integration     Business Flexibility

At Granules, our extensive integration empowers us to meet the unprocessed, semi-processed and processed product needs of our customers
  • Facilities capable of manufacturing products throughout the entire pharmaceutical manufacturing value chain.

  • One of the world’s largest granulation (PFI) plants with a batch-size of 6 MT.

  • Large capacity facilities for Paracetamol and Ibuprofen.

  • Strategic product portfolio focused on high-volume products, such as Paracetamol, Ibuprofen, Guaifenesin, Metformin and other related PFIs and formulations.

  • Catering to a select range of quality-conscious pharmaceutical players.

  • Continually grow capacities commensurately across the value chain.

  • Proposed to enlist a growing number of API/PFI customers for formulations; proposed leverage of marketing infrastructure to gain new customers.

Partnerships/Relationships     Long-term Commitments

At Granules, we strive to be among the largest suppliers in specific products within the global pharmaceutical markets.
  • Supplier of Paracetamol, Ibuprofen, Guaifenesin, Metformin and other related PFIs and formulations to the regulated and quality-conscious markets of the U.S., Europe, Latin America, Australia and Canada.

  • Focus on strengthening relationships with select global MNCs, remain close to their development and add value through our offices in India, U.S., U.K., China and Colombia.

  • Extensive integration provides a growing scope to enhance volumes across select products.

  • Infrastructure designed for large-scale production.

  • One of the largest capacities in the world for Paracetamol and Ibuprofen catering to varying customer needs.

Future Focus: Finished Dosages     High Growth Products

At Granules, we are integrated across the pharmaceutical manufacturing value chain – from APIs to PFIs to FDs.
  • Commenced operations of our finished dosage plantt at Gagillapur in September 2008.

  • Established our capability to manufacture multi-dosage forms – tablets, capsules, collar express, fit and gel caps (soft and hard).

  • Installed a capacity to produce six billion tablets annually, scalable to 12 billion tablets annually with a marginal investment.

  • Filed three ANDAs in 2008-09; plan a proposed filing in 2009-10.

  • Enlisted a prominent U.S. customer for OTC products.

  • Received TGA and EU approval and expecting to receive the U.S.FDA certification for our formulations facility.